U-937 (ATCC® CRL-1593.2)

Organism: Homo sapiens, human  /  Tissue: Pleura/pleural effusion, lymphocyte, Myeloid  /  Disease: histiocytic lymphoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue Pleura/pleural effusion, lymphocyte, Myeloid
Product Format frozen
Morphology monocyte
Culture Properties suspension
Biosafety Level 1
Disease histiocytic lymphoma
Age 37 years
Gender male
Ethnicity Caucasian
Applications
This cell line is suitable as a transfection host
Storage Conditions liquid nitrogen vapor phase
Derivation
The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma.
Clinical Data
37 years
Caucasian
male
The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma.
Receptor Expression
complement (C3)
Genes Expressed
lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA)
Comments
Studies since 1979 have shown that U-937 cells can be induced to terminal monocytic differentiation by supernatants from human mixed lymphocyte cultures,
The cells are negative for immunoglobulin production and Epstein-Barr virus expression.
The cells express the Fas antigen, and are sensitive to TNF and anti-Fas antibodies.
In 1994, PCR and cytogenetic analyses showed that a number of stocks of U-937 were contaminated with the human myeloid leukemia cell line, K-562.
In the earliest stocks available, the level of contamination was 0.6%.
Distribution was discontinued in March 1994, except if required for patent purposes.
Anyone who wishes to receive a sample of this original material should contact the Head of the ATCC Patent Depository.
A stock of CRL-1593 found to be free of K-562 was propagated continuously for 8 weeks and tested weekly by PCR.
Distribution and seed stocks give DNA profiles characteristic of U-937 only.
Such preparations are now offered as authentic U-937 (ATCC CRL-1593.2) and are believed to be free of second subpopulations.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 105 viable cells/mL.
Interval: Maintain cell density between 1 X 105 and 2 X 106 viable cells/mL.
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 12
D13S317: 10,12
D16S539: 12
D5S818: 12
D7S820: 9,11
THO1: 6, 9.3
TPOX: 8,11
vWA: 14, 15
Name of Depositor H Koren
Year of Origin 1974
References

Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890

. Gene expression during normal and malignant differentiation. London: Academic Press; 1985.

. International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980.

Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085

Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653

Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218

Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321

Giovannangeli C, et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA 94: 79-84, 1997. PubMed: 8990164

Brigino E, et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94: 3178-3182, 1997. PubMed: 9096366

Reid YA, et al. Cell Line Cross-contamination of U-937. J. Leukocyte Biol. 57: 804, 1995. PubMed: 7759961

Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577, 1976. PubMed: 178611

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Restrictions

The original U-937 cell line was established by Dr. K. Nilsson's laboratory in 1974 and he has requested the following: (1) In all papers reporting any use of this cell line or any derivatives thereof a direct reference should be made to Sundstrom and Nilsson (Int. J. Cancer 17: 565-577, 1976). (2) Any proposed commercial use of the cells should be negotiated with Professor Kenneth Nilsson, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. (3) No distribution of any of the cells or sublines derived therefrom should be made to third parties; (4) The cells should be used for non-clinical, non-commercial research only.

References

Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890

. Gene expression during normal and malignant differentiation. London: Academic Press; 1985.

. International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980.

Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085

Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653

Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218

Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321

Giovannangeli C, et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA 94: 79-84, 1997. PubMed: 8990164

Brigino E, et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94: 3178-3182, 1997. PubMed: 9096366

Reid YA, et al. Cell Line Cross-contamination of U-937. J. Leukocyte Biol. 57: 804, 1995. PubMed: 7759961

Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577, 1976. PubMed: 178611